Table 2 Animal and human studies evaluating various treatments for corneal neovascularization

Immunomodulation

Lu et al. [28], Zapata et al. [48], Cejkova et al. [49], Park et al. [50]

Cursiefen et al. [47], Ey et al. [51]

Laser treatment

Bucher et al. [56], Sidhu et al. [59]

Baer and Foster [52], Marsh [54], Kumar et al. [55], Sheppard et al. [58]

Fine needle diathermy

–

Faraj et al. [60], Romano et al. [62, 64], Spiteri et al. [63]

Anti-VEGF antibodies

Avisar et al. [75], Lee et al. [76], Lin et al. [78], Ozdemir et al. [80], Kim et al. [81], Bucher et al. [85], Liarakos et al. [86], Kim et al. [87], Akar et al. [88], Dursun et al. [89], Sener et al. [90], Oliveira et al. [92]

Dastjerdi et al. [65], Ferrari et al. [66], Krizova et al. [68], Koenig et al. [77], Chu et al. [79], Kim et al. [82]

Tyrosine kinase inhibitors

Senturk et al. [95], Saishin et al. [96], Onder et al. [97], Pérez-Santonja et al. [98], Kaya et al. [99]

–

Other treatments

Chen et al. [101], Duh et al. [102], Mori et al. [103], Jin et al. [105], Chaoran et al. [106], Dell et al. [107], Berdugo et al. [108], Cloutier et al. [110]

Cursiefen et al. [111, 112]

Combination therapy

Aydin et al. [113], Murata et al. [114], Ozdemir et al. [115], Hoffart et al. [116], Kim et al. [120]

Gerten [117], Hussain and Savant [118], Elbaz [119]